DOCSLIB.ORG

Induction of Labour

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Induction of Labour NHS Forth Valley Induction of Labour Patient Information Leaflet The date of your induction is ___________________________________________________ This will take place in Forth Valley Royal Hospital. You have been given a date to come into hospital for induction of your labour. This leaflet aims to answer some of the questions you may have about what this involves. If you have any other questions please contact a midwife in Triage 01324 567098. What is induction of labour? Labour is a natural process that usually starts on its own between 37 and 42 weeks of pregnancy. Induction of labour is the process of starting labour artificially. Why you might be offered induction? The most common reason for induction of labour is when your baby is overdue. Induction is usually recommended by 42 weeks gestation as after this time the placenta may become less efficient and make complications more likely in some babies (NICE 2008). If your pregnancy has been normal we offer induction between 10 and 14 days after your due date. Induction is sometimes offered for other reasons such as you have raised blood pressure or if it is thought your baby is small. If it is felt that you or your baby’s health is likely to benefit, the Doctor may recommend induction of labour earlier. The Doctor will explain how having your labour induced will help you and your baby. If you are offered induction When induction of labour is being considered your team Midwife or Doctor will discuss your options with you before any decision is reached. This should include explaining the procedure, the care that will be involved, and 2 any risks to you and your baby. If you choose not to go ahead with induction, your Midwife or Doctor will discuss your care options with you. If you decide to have your labour induced your team Midwife will arrange a date with you for admission to antenatal/postnatal ward. This date will depend on availability, as you will realise, only a certain amount of inductions can be safely carried out each day. On occasions, if the ward and or the Unit is very busy, your induction may need to be delayed – if this happens you will be given a full explanation as to the reason and you may be asked to return later that day or the following day. Where will I be induced? You will be given an appointment to go to Forth Valley Royal Hospital. You should have your breakfast before you come to the ward and we also advise you to eat and drink normally whilst on the ward. Your partner is welcome to stay with you during the day but will be asked to go home at 9pm if you are not in labour. If labour does start during the night your partner can be called to be with you in the labour ward. Why might my induction be postponed or delayed? Midwives and doctors understand that, when your IOL is either postponed in the first place or delayed whilst you are in hospital, that you will be very upset. However the safety of you and your baby is paramount and distressing though the event may be a delay may be the safest option. Your induction of labour will be postponed if: l The workload on Delivery Suite means there is no midwife available to care for you at the time l The midwives and doctors have to prioritise mothers and babies for induction of labour, and another mother may have a greater need at the time than you. 3 How is labour induced? Listed below are the ways your labour may be induced. The method chosen depends upon your individual circumstances and how “favourable” your cervix is. A favourable or ripe cervix is when it has become softer and thinner; an unfavourable or unripe cervix is where it is firm, closed and long. You may be offered one or all of these methods to induce your labour: l Pessary or gel l Breaking the bag of waters around the baby (artificial rupture of membranes) l Oxytocin drip A Midwife or a Doctor will perform an internal vaginal examination to assess the cervix; this helps us decide which method of induction is best for you. Priming the cervix l Pessary or gel prostaglandins Prostaglandins are drugs that act like the natural hormones that “triggers off” labour and are used to “prime” the cervix. This process makes the cervix softer and shorter, preparing it for induction of labour. Prostaglandins are inserted into the vagina as a gel or a pessary. What are the risks associated with prostaglandins? Prostaglandins are very safe. Serious side effects from the drugs used are very rare. Some women develop “prostin” contractions, which can be painful, and may cause diarrhoea. Occasionally some women develop a prolonged contraction which can affect the baby’s heart beat. For this reason we will monitor your baby’s heart beat continuously for about 20 minutes before, and 60 minutes after, you have been given the prostaglandin. A small number of women don’t respond to the prostaglandins and we say the induction has “failed”. In these rare cases we may need to perform a caesarean section to deliver the baby. 4 Prostaglandin Pessary A slow releasing prostaglandin pessary which stays in place for 24 hours is given when the cervix is found to be less favourable. Prostaglandin Gel Prostaglandin gel is given when the cervix is more favourable. Sometimes just one dose is required, but many women require more with a second dose given after 6 hours. Some women will require further gel the next day. If your labour has not started after the first day with either the gel or pessary a Doctor or a Midwife will examine you internally the next morning. You may need more prostaglandins or it may be possible to break your waters. How long will it take my labour to start after “priming”? Most women do not go into labour with prostaglandins and labour will be induced as described in the next section once the cervix is favourable. A few women will not respond to the prostaglandins and also there will be some women who over respond and have a very rapid labour without any further treatment. If your labour has not started by the third day a Doctor will come and review you and your baby and discuss your care; you may be given the choice to have a day at home to rest. Occasionally, your induction may last for up to 4-5 days. A Doctor will review you and your baby’s progress daily. What might I expect to feel? After the gel/pessary is given you may experience some crampy like ‘period’ pains, backache and sometimes you may feel a burning sensation in your vagina. You may occasionally feel discomfort at the top of your thighs – this is known as effacement pain (cervix shortening). Please discuss any concerns or symptoms with your midwife. The midwife will check on you and your baby’s wellbeing regularly. 5 What can I do to help the discomfort? l Some women find that walking around eases their discomfort; this can also help to get your labour established. l Do you remember the relaxation and breathing methods you practised in your parentcraft classes? Do not worry if you do not know or remember, the Midwife will tell you about them. l We can give you a ‘hot pack’ to help relieve any backache you may have; your partner could also massage your back for you. l If you have a TENS machine you could use it to help relieve any discomfort. l You could also try a bath or shower – ask the Midwife. l We can also give you pain relieving tablets if you wish, for example Paracetamol. Induction of labour l Breaking the waters to induce labour This is performed by a Midwife or a Doctor during an internal examination. This is usually no more uncomfortable than any other internal examination. A small instrument called an amnihook is used to nick the membranes in front of the baby's head - it looks very much like a crochet hook. This is also called artificial rupture of the membranes (ARM). As this procedure requires your cervix to have started to dilate, it is usually only performed in women who have given birth to a baby before or as in a second step in women who have already had prostaglandin. If your contractions do not start spontaneously, we will recommend you have a drug called syntocinon via a drip (see below). Sometimes we will recommend that the syntocinon drip be started as soon as the waters have been broken. 6 l Syntocinon (oxytocin) drip to induce labour Oxytocin is a drug that is given through a drip into your blood stream. This makes your uterus contract. The rate of the drip is increased until you are having regular strong contractions. It continues until after your baby is born. Whilst having the drip your baby’s heart rate will be continuously monitored. Your ability to walk around will be limited by the drip and monitor although you may choose to stand up, sit in a chair or on a birthing ball. Your waters should usually be broken before oxytocin can be used. When will I go to the labour ward? l When your labour establishes (regular, rhythmic painful contractions accompanied by shortening and dilatation of your cervix). l If your ‘waters’ can be broken, or if your ‘waters’ break naturally during your induction.
Load more

Recommended publications
  • OVESTIN PESSARY (0.5Mg)
    NEW ZEALAND DATA SHEET 1. OVESTIN PESSARY (0.5mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pessary contains 0.5 mg Estriol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pessary 0.5 mg - white, torpedo formed pessary. One pessary (2.5 g weight) contains 0.5 mg oestriol. Length 26.5 mm; largest diameter 14 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Atrophy of the lower urogenital tract related to oestrogen deficiency, notably • for the treatment of vaginal complaints such as dyspareunia, dryness and itching. • for the prevention of recurrent infections of the vagina and lower urinary tract. • in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery. A diagnostic aid in case of a doubtful atrophic cervical smear. 4.2 Dose and method of administration Dosage OVESTIN is an oestrogen-only product that may be given to women with or without a uterus. Atrophy of the lower urogenital tract 1 pessary per day for the first weeks, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1 pessary twice a week) is reached. Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery 1 pessary per day in the 2 weeks before surgery; 1 pessary twice a week in the 2 weeks after surgery. A diagnostic aid in case of a doubtful atrophic cervical smear 1 pessary on alternate days in the week before taking the next smear. Administration OVESTIN pessaries should be inserted intravaginally before retiring at night.
    [Show full text]
  • UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse
    UK Clinical Guideline for best practice in the use of vaginal pessaries for pelvic organ prolapse March 2021 Developed by members of the UK Clinical Guideline Group for the use of pessaries in vaginal prolapse representing: the United Kingdom Continence Society (UKCS); the Pelvic Obstetric and Gynaecological Physiotherapy (POGP); the British Society of Urogynaecology (BSUG); the Association for Continence Advice (ACA); the Scottish Pelvic Floor Network (SPFN); The Pelvic Floor Society (TPFS); the Royal College of Obstetricians and Gynaecologists (RCOG); the Royal College of Nursing (RCN); and pessary users. Funded by grants awarded by UKCS and the Chartered Society of Physiotherapy (CSP). This guideline was completed in December 2020, and following stakeholder review, has been given official endorsement and approval by: • British Association of Urological Nurses (BAUN) • International Urogynecological Association (IUGA) • Pelvic Obstetric and Gynaecological Physiotherapy (POGP) • Scottish Pelvic Floor Network (SPFN) • The Association of Continence Advice (ACA) • The British Society of Urogynaecology (BSUG) • The Pelvic Floor Society (TPFS) • The Royal College of Nursing (RCN) • The Royal College of Obstetricians and Gynaecologists (RCOG) • The United Kingdom Continence Society (UKCS) Review This guideline will be due for full review in 2024. All comments received on the POGP and UKCS websites or submitted here: [email protected] will be included in the review process. 2 Table of Contents Table of Contents ................................................................................................................................
    [Show full text]
  • Pessary for Management of Pelvic Organ Prolapse
    Pessary for management of Pelvic Organ Prolapse Cathy Davis Clinical Nurse Specialist Department of Urogynaecology King’s College Hospital, London Definition of Prolapse The descent of one or more of the anterior vaginal wall, posterior vaginal wall, uterus (cervix) or vaginal vault (cuff scar after hysterectomy). The presence of any such sign should be correlated with relevant POP symptoms. (Haylen et al 2016) Risk Factors • Increased intra-abdominal pressure • Chronic cough • Chronic constipation • Weight lifting • Presence of abdominal tumours - fibroids & ovarian cysts • High impact exercise • Age/ Menopause • Obesity Risk Factors contd.... • Smoking • Multiparity • Congenital weakness – rare; due to deficiency in collagen metabolism • Injury to pelvic floor muscles • Iatrogenic/ pelvic surgery - hysterectomy Symptoms of POP • May be asymptomatic – a small amount of prolapse can often be normal • Sensation of a lump or bulge " coming down" - most common • Backache • Heaviness • Dragging or discomfort inside the vagina – often worse on standing /sitting for prolonged periods • Seeing a lump or bulge Symptoms of POP contd.... • Bladder / Urinary symptoms -Frequency -Difficulty initiating voids, low-flow, incomplete bladder emptying -Leakage on certain movements or when lifting heavy objects -Recurrent urinary tract infections • Bowel symptoms -Constipation - Incomplete bowel emptying - May have to digitate to defecate/use aides • Symptoms related to Sex – uncomfortable, lack of sensation Diagnosis of Prolapse • Vaginal examination •
    [Show full text]
  • Combi Soft Gel Pessary & External Cream
    Combi Soft Gel Pessary Canesten & External Cream 500mg vaginal capsule & 2% w/w cream Clotrimazole Read all of this leaflet carefully because it contains important To treat internal thrush, your doctor may recommend that you use the information for you. pessary without the help of an applicator. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. HOW TO USE CANESTEN® COMBI • This medicine has been prescribed for you. Do not give it to anyone else 3. under any circumstances. The Soft Gel Pessary: • If you have any unusual effects after using this product, tell your doctor. Unless directed otherwise by your doctor, the Soft Gel Pessary should be inserted as high as possible into the vagina, preferably before going to sleep IN THIS LEAFLET at night for convenient and comfortable treatment. Wash your hands before removing the foil from the blister pack and again 1. What is Canesten Combi and what is it used for? afterwards when you have used the applicator. 2. Before you use Canesten Combi 3. How to use Canesten Combi 1. Remove the applicator from the packaging. Pull out the plunger A until it 4. Possible side effects stops. Remove the pessary from the foil blister pack and place firmly into the 5. How to store Canesten Combi applicator B. 6. Further information 1. WHAT IS CANESTEN® COMBI AND WHAT IS IT USED FOR? Canesten Combi Soft Gel Pessary & External Cream is a full course of treatment for vaginal thrush (candidiasis) because it treats both the internal cause and external symptoms.
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release May 28, 2010 / Vol. 59 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 2 and Human Services, Atlanta, GA 30333. How to Use This Document ......................................................... 3 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR Early Release 2010;59[Date]:[inclusive page numbers]. Using the Categories in Practice ............................................... 3 Recommendations for Use of Contraceptive Methods ................. 4 Centers for Disease Control and Prevention Contraceptive Method Choice .................................................. 4 Thomas R. Frieden, MD, MPH Director Contraceptive Method Effectiveness .......................................... 4 Peter A. Briss, MD, MPH Unintended Pregnancy and Increased Health Risk ..................... 4 Acting Associate Director for Science Keeping Guidance Up to Date ...................................................
    [Show full text]
  • Regulations Governing the Classification of Medical Devices (Draft)
    Regulations Governing the Classification of Medical Devices (Draft) Article 1 These Regulations are enacted pursuant to Paragraph 2, Article 3 of the Medical Devices Act (hereinafter “this Act”). Article 2 Medical devices are classified into the following categories according to their function, intended use, operating instructions, and working principle, depending on the applicable medical specialty: 1. Clinical chemistry and clinical toxicology devices 2. Hematology and pathology devices 3. Immunology and microbiology devices 4. Anesthesiology devices 5. Cardiovascular devices 6. Dental devices 7. Ear, nose, and throat devices 8. Gastroenterology and urology devices 9. General and plastic surgery devices 10. General hospital and personal use devices 11. Neurological devices 12. Obstetrical and gynecological devices 13. Ophthalmic devices 14. Orthopedic devices 15. Physical medicine devices 16. Radiology devices Article 3 Medical devices are classified into the following classes according to their risk level: 1. Class I: Low risk 2. Class II: Medium risk 3. Class III: High risk 1 Article 4 Product items of the medical device classification are specified in the Annex. In addition to rules stated in the Annex, medical devices whose function, intended use, or working principle are special may have their classification determined according to the following rules: 1. If two or more categories, classes, or product items are applicable to the same medical device, the highest class of risk level is assigned. 2. The accessory to a medical device, intended specifically by the manufacturer for use with a particular medical device, is classified the same as the particular medical device, unless otherwise specified in the Annex. 3.
    [Show full text]
  • Vaginal Support Pessaries: Indications for Use and Fitting Strategies
    SERIES Vaginal Support Pessaries: Indications for Use and Fitting Strategies Shanna Atnip and Katharine O’Dell ESSARIES P elvic floor disorders are © 2012 Society of Urologic Nurses and Associates common in women, and as the population ages, Atnip, S., & O’Dell, K. (2012). Vaginal support pessaries: Indications for use and these disorders may be fitting strategies. Urologic Nursing, 32(3), 114-125. Pseen more frequently by health ERIES ON care providers (Nygaard et al., Flexible silicone vaginal support pessaries offer a low-risk, effective option for S 2008). When pelvic symptoms treatment of symptoms of pelvic organ prolapse. This first article in a three-part series summarizes clinical recommendations and current evidence related to are associated with loss of struc- pessary indications, choice, and fitting. tural support of the pelvic organs and vagina, vaginal support pes- PECIAL Key Words: Pelvic organ prolapse, pessary, indications, fitting. saries offer an important option S for relief (American College of Objectives: Obstetricians & Gynecologists 1. List the symptoms of pelvic organ prolapse that may be successfully treated [ACOG], 2007). with a vaginal support pessary. Historically, vaginal pessaries have been used to manage pelvic 2. Discuss the various types of pessaries and their uses to treat pelvic organ floor relaxation and were made prolapse. from a variety of materials, 3. Outline the pessary selection process and steps to pessary fitting. including fruit, metal, porcelain, rubber, and acrylic (Shah, Sultan, genic, and washable, and can gen- & Thakar, 2006). Modern pessaries erally be sterilized using an auto- are made from silicone, acrylic, clave, boiling water, or a cold ster- Shanna Atnip, MSN, WHNP-BC, is a Nurse latex, or rubber.
    [Show full text]
  • Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices
    September 12, 2006 NOTICE Our file number: 06-120629-368 Re: Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices Health Canada is pleased to announce the release of the revised Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices. This guidance document supersedes the January 14, 2000 version of the same document. The Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices is intended to assist manufacturers in confirming the classification of medical device products after application of the Classification Rules for Medical Devices set out in Schedule 1 of the Medical Devices Regulations. This guidance document has been revised to reflect changes to the risk- based classification of particular medical device groups. Specifically, the following major changes have been made to the document: • the reclassification of specific medical device groups; • the removal of redundant information; • the addition of medical device groups; and • the omission of product groups that do not fit the meaning of a medical device as defined in the Food and Drugs Act. To search for a medical device group within the Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices PDF file, go to Edit/Find and enter a keyword, preferred name code or description in the “Find” field. For instance, to verify the risk-based classification of dental burs, enter “bur” or “drill” in the “Find” field. Please note that this guidance document is provided only as a guide and that in the event of any discrepancy between this document and the Classification Rules for Medical Devices described in the Medical Devices Regulations, the latter shall prevail.
    [Show full text]
  • Treatment of Recurrent Vulvo-Vaginal Candidiasis with Sustained-Release Butoconazole Pessary
    C ase R eport Singapore Med J 2012; 53(12) : e269 Treatment of recurrent vulvo-vaginal candidiasis with sustained-release butoconazole pessary Ling Zhi Heng1, MBBS, Yujia Chen1, MBBS, Thiam Chye Tan1,2, MBBS, MMed ABSTRACT Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no optimal or recommended regime for RVVC. Although antifungal agents, such as imidazoles, have been successfully used as a first-line treatment for acute VVC, its effectiveness is limited in RVVC. This could be due to patient factors, drug application (such as leakage) or dosing factors. A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug. We describe its efficacy and the successful use of a butoconazole-SR formulation in the treatment of two cases of RVVC. Keywords: butoconazole, candidiasis, recurrent vulvo-vaginal Singapore Med J 2012; 53(12): e269–e271 INTRODUCTION Table I. Risk factors for recurrent vulvo-vaginal candidiasis. Candidiasis is a common cause of infective vaginal discharge Risk factors Examples experienced by women. 75% of women experience at least Microbial • Candida albicans species one episode of vaginitis during their lifetime. Recurrent vulvo- • Non-albicans Candida species vaginal candidiasis (RVVC) is defined as four or more episodes Host • Uncontrolled diabetes mellitus • Oestrogen excess – oral contraceptive pills, hormone of symptomatic vulvo-vaginal cadidiasis (VVC) in one year. Up replacement therapy, local oestrogen administration, to 5% of women of childbearing age have experienced RVVC.(1) pregnancy Common symptoms include vaginal discharge, vulvar pruritus, • Antibiotic-induced dyspareunia and dysuria.
    [Show full text]
  • Drug-N-Therapeutics-Committee.Pdf
    Irrational use of medicines is a widespread problem at all levels of health care, but especially GUIDE DRUG AND THERAPEUTICS COMMITTEES: A PRATICAL in hospitals. This is particularly worrying as resources are generally scarce and prescribers in communities often copy hospital prescribing practices. Use of medicines can be greatly improved and wastage reduced if some simple principles of drug management are followed. But it is difficult to implement these principles because staff from many different disciplines are involved, often with no forum for bringing them together to develop and implement appropriate medicines policies. A drug and therapeutics committee (DTC) provides such a forum, allowing all the relevant people to work together to improve health care delivery, whether in hospitals or other health facilities. In many developed countries a well functioning DTC has been shown to be very effective in addressing drug use problems. However, in many developing countries DTCs do not exist and in others they do not function optimally, often due to lack of local expertise or a lack of incentives. Drug and Therapeutics Committees: A Practical Guide provides guidance to doctors, pharmacists, hospital managers and other professionals who may be serving on DTCs and/or who are concerned with how to improve the quality and cost efficiency of therapeutic care. It is relevant for all kinds of DTCs - whether in public or private hospitals and whether at district or tertiary referral level. This comprehensive manual covers a committee’s functions and structure, the medicines formulary process, and how to assess new medicines. The chapters on tools to investigate drug use and strategies to promote rational use are followed by a discussion of antimicrobial resistance and infection control.
    [Show full text]
  • Standard Terms: Introduction and Guidance for Use – V.2.1.3 – 16 November 2018 Contents
    Standard Terms Introduction and Guidance for Use Version 2.1.3 – 16 November 2018 GENERAL PRINCIPLES AND INSTRUCTIONS FOR USE OF THE LISTS OF STANDARD TERMS The lists of Standard Terms were initially drawn up by the European Pharmacopoeia (Ph. Eur.) Commission further to a request of the EU Commission, for use in marketing authorisation applications (MAAs), labelling (including the summary of product characteristics (SmPC)), and electronic communications. The first list was published as a special edition of Pharmeuropa in October 1996. The European Directorate for the Quality of Medicines & HealthCare (EDQM), a Directorate of the Council of Europe based in Strasbourg, France, is responsible for continuing this work. Standard Terms have the double purpose of bringing information to the patient/user/prescriber and distinguishing medicinal products having the same trade-name. Because of the labelling purposes it is imperative that any Standard Term is constructed with a view to the patient and the prescriber. It conveys essential information on the properties and uses of the particular medicinal products. To avoid a proliferation of over-complicated terms, complete information cannot always be included in a Standard Term, and should instead appear elsewhere in the labelling, in particular the package leaflet and SmPC. Since 2017 the scope of the Standard Terms database has also widened to allow the inclusion of certain additional terms that are not intended for use in MAAs, but are used for related purposes such as adverse event reporting (pharmacovigilance) and clinical trials. At the same time, in an effort to encourage greater global harmonisation of electronic communications, applications for terms to describe concepts that are not used in European Pharmacopoeia Commission member states but are used in other regions are also now accepted for consideration.
    [Show full text]
  • Induction of Labour This Is an Update of NICE Inherited Clinical Guideline D
    Issue date: July 2008 Induction of labour This is an update of NICE inherited clinical guideline D NICE clinical guideline 70 Developed by the National Collaborating Centre for Women’s and Children’s Health NICE clinical guideline 70 Induction of labour Ordering information You can download the following documents from www.nice.org.uk/CG070 • The NICE guideline (this document) – all the recommendations. • A quick reference guide – a summary of the recommendations for healthcare professionals. • ‘Understanding NICE guidance’ – information for patients and carers. • The full guideline – all the recommendations, details of how they were developed, and reviews of the evidence they were based on. For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email [email protected] and quote: • N1625 (quick reference guide) • N1626 (‘Understanding NICE guidance’). NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales. This guidance represents the view of the Institute, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer and informed by the summary of product characteristics of any drugs they are considering. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity.
    [Show full text]